STAT3-IN-17 

STAT3-IN-17 is a moderate STAT3 inhibitor (IC₅₀=0.7 μM; HEK-Blue IL-6), with antiproliferative activity in HeLa cells. STAT3-IN-17 has good pharmacokinetic characteristics. STAT3-IN-17 also inhibits pyruvate-ferredoxin oxidoreductase (PFOR), and inhibits Helicobacter pylori^[1][2].

STAT3-IN-17 (compound 15) (10 μM; 20 h, 48 h) inhibits STAT3 pathway with inhibition rate of 76.5%, and also inhibits HEK-Blue IL-6 cells viability to 15%^[1].
STAT3-IN-17 (2.5-40 μM; 24 h) inhibits the phosphorylation of STAT3 (Y705)^[1].
STAT3-IN-17 (10 μM, 50 μM; 48 h) inhibits HEK 293T cell growth, as well as inhibiting HeLa cell growth with an IC₅₀ value of 2.7 μM^[1].
(D)-PPA 1 (compound 24) inhibits microorganisms Helicobacter pylori and Campylobacter jejuni with MIC values of 1.6 μM and 4.7 μM, respectively^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

STAT3-IN-17 (compound 15) (5 mg/kg for ig, or 25 mg/kg for iv; single dose) exhibits greater pharmacokinetic properties than Nitazoxanide (HY-B0217) in rat, with a significantly longer half-life for elimination (t1/2β) (11.1 vs 0.8 h), greater absolute bioavailability (F) (87.4% vs 5.7%), and higher maximum plasma concentration (Cmax) (20.7 vs 1.0 mg/L) maximum plasma concentration (Cmax) (20.7 vs 1.0 mg/L)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

317.24

C₁₁H₆F₃N₃O₃S

1245814-52-1

O=C(NC1=NC=C([N+]([O-])=O)S1)C2=CC=C(C(F)(F)F)C=C2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Lü Z, et al. Structure-Activity Study of Nitazoxanide Derivatives as Novel STAT3 Pathway Inhibitors. ACS Med Chem Lett. 2021 Apr 1;12(5):696-703.  [Content Brief]